Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in the context of low testosterone (without or alongside trt) in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

Randomized double-blind crossover design of placebo versus testosterone administration in healthy older men.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Deconvolution analysis was used to estimate basal GH secretion and the mass (integral) and waveform (time-shape) of GH secretory bursts.

What Was Measured

PubMed files the paper under topics including Adipose Tissue, Aging, Arginine, Drug Combinations, Growth Hormone-Releasing Hormone, Human Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in people with low testosterone (without or alongside trt).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, Low testosterone (without or alongside TRT) research.